doxifluridine has been researched along with sodium oxybate in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K | 1 |
1 other study(ies) available for doxifluridine and sodium oxybate
| Article | Year |
|---|---|
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carcinoma, Renal Cell; Chemotaxis; Colonic Neoplasms; DNA Replication; Drug Combinations; Endothelial Growth Factors; Endothelium, Vascular; Female; Fibroblast Growth Factor 2; Floxuridine; Fluorouracil; Humans; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Lung Neoplasms; Lymphokines; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Neoplasm Proteins; Neovascularization, Pathologic; Prodrugs; Prostheses and Implants; Recombinant Proteins; Sodium Oxybate; Stomach Neoplasms; Tegafur; Tumor Cells, Cultured; Uracil; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2001 |